BOSTON and ATLANTA, May 10, 2022
/PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq:
IKT) (Inhibikase), a clinical-stage pharmaceutical company
developing therapeutics to modify the course of Parkinson's disease
and related disorders, today announced that Dr. Milton Werner, Ph.D., the Company's President
& Chief Executive Officer will present at the upcoming H.C.
Wainwright Global Investment Conference being held in Miami Beach, FL on May
25, 2022 at 2:30 pm ET.
About Inhibikase (www.inhibikase.com)
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage
pharmaceutical company developing therapeutics for Parkinson's
disease and related disorders. Inhibikase's multi-therapeutic
pipeline focuses on neurodegeneration and its lead program
IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets
the treatment of Parkinson's disease inside and outside the brain.
Its multi-therapeutic pipeline is pursuing Parkinson's-related
disorders of the brain and GI tract, orphan indications related to
Parkinson's disease such as Multiple System Atrophy, and drug
delivery technologies for kinase inhibitors such as IkT-001Pro, a
prodrug of the anticancer agent Imatinib that the Company believes
will provide a better patient experience with fewer on-dosing
side-effects. The Company's RAMP™ medicinal chemistry program has
identified a number of follow-on compounds to IkT-148009 to be
potentially applied to other cognitive and motor function diseases
of the brain. Inhibikase is headquartered in Atlanta, Georgia with offices in Boston, Massachusetts.
Social Media Disclaimer
Investors and others should
note that we announce material financial information to our
investors using our investor relations website, press releases, SEC
filings and public conference calls and webcasts. The Company
intends to also
use Twitter, Facebook, LinkedIn and YouTube as
a means of disclosing information about the Company, its services
and other matters and for complying with its disclosure obligations
under Regulation FD.
Contacts:
Company Contact:
Milton H.
Werner, PhD
President & CEO
678-392-3419
info@inhibikase.com
Investor Relations:
Alex
Lobo
SternIR, Inc.
alex.lobo@sternir.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/inhibikase-therapeutics-to-participate-at-the-hc-wainwright-global-investment-conference-301542540.html
SOURCE Inhibikase Therapeutics, Inc.